Jointly sponsored by NASPGHAN and The NASPGHAN Foundation for Children’s Digestive Health and Nutrition.

Release Date: June 1, 2014, Expiration Date: May 31, 2017

2.0 AMA PRA Category 1 CME Credits™

Chair

Rohit Kohli, MBBS, MS
Associate Professor of Pediatrics
Medical Director, Complex Surgery and Transplant Inpatient Unit
Co-Director, Steatohepatitis Center
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Faculty

Ruba K. Azzam, MD
Associate Professor of Pediatrics
Medical Director, Pediatric Liver Transplant Program
University of Chicago
Comer Children’s Hospital
Chicago, IL

Regino P. Gonzalez-Peralta, MD
Professor of Pediatrics
Assistant Dean, Office of Diversity and Health Equity
University of Florida College of Medicine
Gainesville, FL

Maureen Jonas, MD
Clinical Director, Hepatology
Medical Director, Liver Transplant Program
Boston Children’s Hospital
Professor of Pediatrics
Harvard Medical School
Boston, MA

CME Content Reviewer

Henry Lin, MD
Attending Physician
The Children’s Hospital of Philadelphia
Philadelphia, PA

Medical Writer

Matt Kilby
Science Writer

Masqueraders of Nonalcoholic Fatty Liver Disease
A CME Case-Based Newsletter

Jointly sponsored by NASPGHAN and The NASPGHAN Foundation for Children’s Digestive Health and Nutrition.

This educational activity is supported by an independent medical education grant from Synageva.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States, affecting an estimated 10%-46% of the US population and somewhere between 3% and 25% of children. Obesity is the most common cause of NAFLD; however, 3%-10% of pediatric patients with NAFLD are nonobese. It is important to understand potential causes of NAFLD that are not obesity related to avoid misdiagnosis in pediatric patients. These include but are not limited to mitochondrial hepatopathies, kwashiorkor/anorexia nervosa, Wilson’s disease, cholesteryl ester storage disease (CESD)/lysosomal acid lipase (LAL) deficiency, hepatitis C, uncontrolled type 1 diabetes, and mitochondrial disorders.

Physicians must recognize clues that fatty liver might not be the typical obesity-associated NAFLD. The real-life cases presented here illustrate these clinical clues and help providers decide which patients should have additional testing, as well as which tests should be considered. Once proper diagnoses are made, the cases also consider appropriate treatment approaches for patients with these “masqueraders of NAFLD.”

Target Audience
This activity is designed for pediatricians, pediatric gastroenterologists and hepatologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who treat patients at risk for NAFLD.

Learning Objectives
Participants completing this activity should be better able to:
- Recognize disease types of NAFLD in nonobese pediatric patients, such as Wilson’s disease, lysosomal acid lipase deficiency, and Alpers syndrome
- Describe the pathophysiology of NAFLD disease types in nonobese pediatric patients, including disease definitions and causes
- Describe recommended strategies for diagnosing different types of NAFLD in nonobese pediatric patients
- Describe appropriate and evidence-based treatments for NAFLD in nonobese pediatric patients

Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and The NASPGHAN Foundation for Children’s Digestive Health and Nutrition. NASPGHAN is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Statement
NASPGHAN designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Disclosure
All faculty/speakers, planners, abstract reviewers, moderators, authors, coauthors, and administrative staff participating in the continuing medical education programs sponsored by NASPGHAN are expected to disclose to the program audience any/all relevant financial relationships related to the content of their presentation(s). Accordingly, the NASPGHAN staff have reported no financial relationships with any commercial interests related to the content of this educational activity.

Rohit Kohli, MBBS, MS was on Synageva’s speakers bureau and relationship has ended.
Ruba K. Azzam, MD has nothing to disclose.
Regina P. Gonzalez-Peralta, MD has received honoraria from Synageva.
Maureen Jonas, MD has nothing to disclose.
Henry Lin, MD has nothing to disclose.
Matt Kilby has nothing to disclose.

Policy on Privacy and Confidentiality
NASPGHAN and The NASPGHAN Foundation for Children’s Digestive Health and Nutrition will make every effort to protect the privacy of every individual participant of this activity and will use information gathered only to maintain records as required by the American Medical Association (AMA) and ACCME.

This activity does not require readers to “register” to review the material, with the exception of physicians and other health care providers who desire to receive CME credit for this accredited activity. If an individual completes a CME for this accredited activity, we are required by the AMA and ACCME to collect personal information on the individual, such as their name, address, and phone number, that will allow us to issue a CME certificate to them and to keep this information on file for up to 6 years.

Personal information gathered will not be released to any other company or organization for any purpose. This information remains totally confidential.

© Copyright 2014 NASPGHAN and The NASPGHAN Foundation for Children’s Digestive Health and Nutrition.
**Introduction**

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States, affecting an estimated 10%–46% of the US population and somewhere between 3% and 25% of children. Obesity is the most common cause of NAFLD; however, 3%–10% of pediatric patients with NAFLD are nonobese. It is important to understand potential causes of NAFLD that are not obesity related to avoid misdiagnosis in pediatric patients. These include but are not limited to mitochondrial hepatopathies, kwashiorkor/anorexia nervosa, Wilson’s disease, cholesteryl ester storage disease (CESD)/lysosomal acid lipase (LAL) deficiency, hepatitis C, uncontrolled type 1 diabetes, and mitochondrial disorders.

Physicians must recognize clues that fatty liver might not be the typical obesity-associated NAFLD. The real-life cases presented here illustrate these clinical clues and help providers decide which patients should have additional testing, as well as which tests should be considered. Once proper diagnoses are made, the cases also consider appropriate treatment approaches for patients with these “masqueraders of NAFLD.”

**Case Study 1: Javier**

Javier is a 13-year-old Hispanic boy referred for evaluation of liver test abnormalities. He was diagnosed with hypothyroidism (and started on levothyroxine) approximately 1 year ago, when laboratory testing for fatigue showed elevated thyroid-stimulating hormone (TSH). At the time, he also had elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels (greater than twice the upper limit of normal), which persisted on several subsequent determinations. Other than experiencing mild, vague, and intermittent right upper quadrant abdominal pain over the preceding 3 days, he is completely asymptomatic. There are no lung, liver, or neurological complaints. His mother has hypothyroidism; no relatives have liver, lung, neurological, or psychiatric disease.

The weight is 69 kg (>95%), the height is 162 cm (60%), and the body mass index (BMI) is 26 kg/m² (>95%). He has abdominal striae. Neither the liver nor spleen is enlarged, and there are no stigmata of chronic liver disease. Results of complete blood count (CBC), prothrombin time, TSH, and liver tests are normal except for elevated AST and ALT (132 and 120 IU/L, respectively). Liver-specific tests, including antinuclear, smooth muscle, and liver-kidney microsomal antibodies; hepatitis A and C serology; hepatitis B surface antigen; creatinine kinase; and alpha 1 antitrypsin level and Pi phenotype are normal; the ceruloplasmin concentration is low (8 mg/dL [normal > 20 mg/dL]); and there is borderline hepatomegaly on abdominal sonogram with increased echogenicity consistent with fatty infiltration of the liver.
**Wilson’s Disease**

**Pathophysiology**

Wilson’s disease is an autosomal recessive disease that affects 3–30 in every 1 million individuals. It is caused by mutation in the ATP7B gene, which encodes a metal-transporting adenosine triphosphatase that aids in the transmembrane transport of copper. Alterations in ATP7B protein function leads to copper accumulation in the liver and results in injury as excess copper is released into the blood and deposited in various organs, including the brain, cornea, heart, kidneys, and pancreas.

The original clinical description of Wilson’s disease was in a group of patients between ages 5 and 40 years with necrotic damage in lenticular nuclei and liver cirrhosis. Later descriptions included neurologic manifestations and Kayser-Fleischer (KF) rings—copper deposition in the cornea that appears as a ring of golden brownish pigment near the limbus. An important biochemical feature of Wilson’s disease is decreased serum ceruloplasmin concentration.

In most cases, Wilson’s disease presents clinically as either a liver, neurological, or psychiatric disorder. In children, liver dysfunction is the most common initial presenting scenario, occurring in 50% of affected pediatric patients under age 18 years and 75% under age 10 years. Copper toxicity is rarely evident before ages 3–5 years, and manifestations include asymptomatic elevations of transaminases, acute or chronic hepatitis, cirrhosis, and acute liver failure. Neurological or psychiatric signs are the first indication of illness in 40%–45% of patients with Wilson’s disease and have been recorded in children as young as age 6 years. Neurological symptoms include tremors, drooling, poor coordination, ataxia, writing difficulties, dementia, anxiety or depression, psychosis, and schizophrenia.

**Diagnosis**

Patients with Wilson’s disease may present with vague, mild, and varied symptoms that can make diagnosis challenging. Because no single conclusive test exists to detect or exclude Wilson’s disease, clinical findings and biochemical testing need to be incorporated to establish a firm diagnosis (Figure 1).

**Figure 1.** Diagnostic Approach to Wilson’s Disease

![Diagram of diagnostic approach to Wilson's disease](https://example.com/diagram.png)
A diagnosis of Wilson’s disease should be considered in any child over the age of 3 years who presents with unexplained liver test abnormalities. Patients with suspected Wilson’s disease should undergo careful slit lamp examination by an experienced examiner to assess for the presence of KF rings, although the absence of these rings does not exclude diagnosis, even in patients with predominantly neurological symptoms. Routine measurement of serum ceruloplasmin is also recommended during evaluation of unexplained hepatic, neurologic, or psychiatric symptoms, with an extreme low (<50 mg/L or 5 mg/dL) indicative of Wilson’s disease. However, normal ceruloplasmin levels do not necessarily exclude Wilson’s disease.

In patients without both KF rings and normal serum ceruloplasmin concentration, additional testing is necessary to assess for Wilson’s disease. Basal 24-hour urinary excretion of copper aids in the diagnosis of the disease. Copper levels in an appropriately collected urine sample >100 μg/24 hours in symptomatic patients indicate Wilson’s disease, whereas those >40 μg/24 hours require further investigation. Urine copper levels >1600 μg/24 hours with the administration of D-penicillamine (500 mg at the start of the collection and 12 hours into it) may provide additional evidence for the presence of Wilson’s disease.

In addition to serological and urinary testing, hepatic copper content and histology provide important information, with >250 μg/g dry liver tissue weight providing the strongest biochemical evidence for Wilson’s disease and normal values (<40–50 μg/g dry liver tissue) excluding this diagnosis. Typical histologic abnormalities seen in Wilson’s disease include micro- and macrovesicular steatosis, glycogenated nuclei in hepatocytes, and focal hepatocellular necrosis. With confirmed diagnosis of Wilson’s disease, any first-degree relatives of the patient should also be screened by either biochemical or genetic testing.

**Treatment**

Chelating agents are typically recommended as the initial treatment in patients with active or symptomatic Wilson’s disease. Penicillamine is used most often, but trientine is becoming increasingly popular as the primary therapy. While using either chelating agent, care should be taken to slowly increase the dose to reach the initial target (Table 1). Combination therapy of zinc used with a chelating agent (separated temporally) could theoretically block copper uptake and eliminate excess copper; however, this has only been studied...
in preliminary reports and efficacy over treatment with a chelator alone has not yet been determined. Additionally, ongoing studies are investigating the use of tetrathiomolybdate as an alternative chelator for initial treatment in patients with neurologic symptoms. Vitamin E can also be considered for use as an antioxidant. These treatments are further detailed in Table 1.

Once symptoms or biochemical abnormalities stabilize (typically 2–6 months after therapy initiation), maintenance doses of chelators or zinc can be used, and treatment is lifelong. Zinc monotherapy can be considered in presymptomatic patients who are identified by family screening. Poor treatment adherence can result in recurrent symptoms and liver failure, which requires liver transplantation. Therefore, it is important for the physician to monitor patients for compliance as well as potential adverse effects of treatment.

**Case Study 1: Follow-Up**

Javier’s initial low ceruloplasmin concentration suggests Wilson’s disease. He has no KF rings by slit lamp examination. Results of a 24-hour urine copper (140 μg) and hepatic copper content (846 μg/g dry liver tissue) are markedly elevated and confirm diagnosis of Wilson’s disease. Javier is started on trientine monotherapy.

### Table 1. Treatment Approach for Wilson’s Disease

<table>
<thead>
<tr>
<th>Drug</th>
<th>Action</th>
<th>Dose</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillamine</td>
<td>Chelator</td>
<td>Initial 20 mg/kg/day (1.5–2 g/day) given in 2 or 3 divided doses</td>
<td>Generalized pruritus, Early and late rashes, Anorexia, Gastronintestinal pain, Nausea, Vomiting, Diarrhea, Blunting, diminution, or total loss of taste perception, Leukopenia, Thrombocytopenia, Proteinuria, Hematuria, Tinnitus, Optic neuritis, Dystonia</td>
</tr>
<tr>
<td>Trientine</td>
<td>Chelator</td>
<td>Initial 20 mg/kg/day (1.5–2 g/day) given in 2 or 3 divided doses</td>
<td>Iron deficiency, Systemic lupus erythematosus, Dystonia, Muscular spasm, Myasthenia gravis</td>
</tr>
<tr>
<td>Zinc</td>
<td>Blocks absorption</td>
<td>75–150 mg/day (in 3 divided doses)</td>
<td>Gastric irritation</td>
</tr>
<tr>
<td>Tetrathiomolybdate</td>
<td>Chelator Blocks absorption</td>
<td>150–200 mg/day</td>
<td>Anemia, Neutropenia, Leukopenia, Transaminase elevations</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>Antioxidant</td>
<td>400–1200 IU/day</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Case Study 2: Alina

Alina is a 13-year-old girl of Polish American descent who is referred by her primary physician for abnormal liver enzymes, hepatomegaly, and fatty liver observed by ultrasound. She has been previously healthy but, over the past 6 months, has constantly felt tired. Thyroid function test results are normal. She does not have symptoms of abdominal pain, fever, jaundice, itching, bleeding, cold intolerance, or irregular defecation. She has not lost or gained weight but is smaller in size than her peers. She does not currently take any medicine or herbal therapies and eats a typical American diet, though she does not exercise much on a regular basis. On physical examination, her BMI is 22 kg/m² and she has hepatomegaly but no signs of chronic liver disease. Her most recent laboratory workup includes an AST level of 56 IU/L (increased from 55 IU/L 3 months earlier), ALT level of 67 IU/L (decreased from 77 IU/L), high-density lipoprotein (HDL) of 35 mg/dL (decreased from 40 mg/dL), low-density lipoprotein (LDL) of 292 mg/dL (increased from 262 mg/dL), and triglyceride (TG) of 122 mg/dL (decreased from 135 mg/dL). Computed tomography of her abdomen reveals diffuse low attenuation of liver parenchyma compatible with fatty infiltration, and the maximum craniocaudal length of her liver is 20 cm.

Lysosomal Acid Lipase Deficiency

Pathophysiology

LAL deficiency presents clinically in 2 phenotypes: the infantile-onset Wolman disease (WD) and later-onset CESD. WD occurs in 1 in 500,000 infants, usually between the ages of 2–4 months. In these infants, LAL activity is absent or decreased to <1% of normal values, causing massive lysosomal accumulation of cholesteryl esters (CEs) and TGs, predominantly in the liver, spleen, adrenals, bone marrow, lymph nodes, and in macrophages throughout the body, particularly in the intestinal villi. Infants present with vomiting, diarrhea, massive hepatosplenomegaly (HSM), severe liver disease, adrenal calcifications in 50% of cases, feeding difficulties, malabsorption, malnutrition, and growth retardation. It often leads to patient death by age 12 months.

CESD is an autosomal recessive lysosomal storage disorder that occurs in 1 in 40,000 people and results from mutation in the LAL gene (LIPA) that cause marked reduction in LAL activity. As a result, CEs accumulate throughout the body. The degree of accumulation usually correlates with the tissues’ relative participation in receptor-mediated endocytosis and lysosomal degradation of lipoproteins. Organs that are predominantly affected are the liver, spleen, adrenals, bone marrow, lymph nodes, and intestinal villi. Defective LAL activity reduces hydrolysis of CEs and TGs and causes massive sequestration, particularly in Kupffer cells and hepatocyte lysosomes as well as other cells of the macrophage/m很重要ocyte system. Lack of free cholesterol due to lysosomal trapping of CEs leads to reduced feedback inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, which in turn leads to increased synthesis of cholesterol and upregulation of apolipoprotein B synthesis and LDL receptors on cell membranes. The dysregulated expression of the LDL cholesterol–dependent adenosine triphosphate–binding cassette transporter 1 gene contributes to HDL cholesterol reduction.

CESD may present in infancy, childhood, or adulthood, depending on the residual in vitro LAL activity (1%-12% of normal) and is underrecognized, especially in patients of European ancestry and Persian Jews. It is commonly misdiagnosed as NAFLD, nonalcoholic steatohepatitis, or cryptogenic liver disease. It presents as hepatomegaly and liver dysfunction and/or type IIb dyslipoproteinemia (increase in total cholesterol [Tchol], LDL, and TG and decrease in HDL). Liver tissue in patients with CESD is grossly bright yellow-orange in color, and histology reveals massive lysosomal accumulation of CEs and TGs in hepatocytes,
Kupffer cells, and macrophages, giving the microvesicular steatosis picture. Progressive lipid deposition leads to fibrosis, micronodular cirrhosis, and ultimately liver failure.

**Diagnosis**

The rarity of LAL deficiency makes it easy to miss or misdiagnose, but various diagnostic and screening tools are available for appropriate diagnosis. Typical diagnosis is based on laboratory evaluation demonstrating transaminitis and/or dyslipidemia. Hepatomegaly or HSM is a common finding on physical examination. Fatty infiltration is seen on radiological or histological evaluation. Symptoms can be nonspecific and include diarrhea, abdominal pain, malabsorption, or those related to cholestasis or cardiovascular disease or early stroke. Clinical suspicion for CESD is confirmed via genetic testing. Over 40 loss-of-function LIPA mutations have been identified in patients with LAL deficiency, with E8SJM being the most common mutation. Traditional enzyme assays for LAL activity in peripheral leukocytes, cultured fibroblasts, or liver tissue have been used. More recently, dried blood spot (DBS) analysis for LAL activity has become available as a simple and more-specific assay for LAL enzyme activity, with a good separation of the activities of normal controls and CESD homozygotes and heterozygotes. It uses 4-methylumbelliferyl-palmitate as the enzyme substrate and the LAL-specific inhibitor, Lalistat 2.

Available laboratories in the United States for DBS and LIPA sequencing analysis are provided in **Table 2**.

**Treatment**

There is currently no approved treatment for LAL deficiency, although liver transplantation has been effective in preventing liver failure and subsequent death. Extrahepatic organ involvement, even in transplanted patients, can result in significant disease burden and premature death.

Sebelipase alfa is currently under investigation as a potential enzyme-replacement therapy for patients with LAL deficiency. In preclinical trials, this recombinant human LAL enzyme effectively reversed lipid storage in the liver, decreased lipid concentration in key tissues, normalized liver function, and corrected clinically relevant abnormalities, including liver size and growth failure, in the first human study, 9 patients received 4 weekly infusions of sebelipase alfa at doses of 0.35, 1, or 3 mg/kg. At week 12 compared to baseline. At week 12, the same 7 patients also had mean decreases in Tchol (22%), LDL cholesterol (27%), and TGs (28%) and increases in HDL cholesterol (15%). Further clinical trials for sebelipase alfa are ongoing, and enrollment in one of these studies may be a viable option for therapy.

**Case Study 2: Follow-Up**

Alina’s elevated ALT, dyslipidemia, and fatty liver on radiology evaluation in the absence of being overweight or obese leads to further evaluation, including a liver biopsy and LAL assay through DBS testing. Liver biopsy shows enlarged hepatocytes with high lipid content, and LAL enzyme activity is <0.02 pmol/punch/hour (normal limit 24–134 pmol/punch/hour). Alina is diagnosed with CESD. Although there is currently no approved therapy, ongoing trials should be monitored for a potential avenue for treatment.

| **Table 2. US Laboratories for DBS Testing and LIPA Gene Sequencing** |
|-----------------|-----------------|-----------------|
| **LABORATORY**                           | **CONTACT INFORMATION**                                                       | **AVAILABLE TEST** |
| Laboratory Corporation of America (Research Triangle Park, NC) | Phone: (800) 345-4363  
Web site: www.labcorp.com/wps/portal/provider/testmenu  
LAL deficiency test code: 402300 | DBS |
| Massachusetts General Hospital, Neurogentics DNA/Biochemical Diagnostics Lab (Boston, MA) | Phone: (617) 726-5721  
Web site: www.massgeneral.org/research/resourcelab.aspx?id=43 | DBS, LIPA |
| Seattle Children’s Hospital, Biochemical Genetics Laboratory | Phone: (206) 9872216  
Web site: www.seattlechildrens.org/labman | DBS |
Alpers Syndrome

Pathophysiology

Alpers-Huttenlocher syndrome (Alpers syndrome) is an inherited, monogenic, autosomal recessive disorder that occurs in approximately 1 in 100,000 patients. It is caused by mutation of the POLG gene, which is the sole polymerase replicating mitochondrial DNA (mtDNA). POLG mutations can result in a reduced number of mtDNA copies in the muscle, brain, and liver cells, causing a decrease in cellular energy that manifests in typical Alpers syndrome signs and symptoms and eventually leads to fatal brain and liver disease in children and young adults. Onset of Alpers syndrome usually occurs in early childhood (age 2–4 years), although it can occur later. The typical presentation includes 3 factors: refractory seizures including a focal aspect, psychomotor regression (often episodic), and liver disease. Additional symptoms may include ataxia and neuropathy that can lead to areflexia. Affected patients may also develop hypotonia that worsens until they can no longer control their muscles and movement, myoclonus, choreoathetosis, or parkinsonism. Migraines with visual sensations or auras are common, and patients may also have fatigue, inability to concentrate, irritability, memory loss, loss of language skills, and eyesight or hearing loss.

Diagnosis

A diagnosis of mitochondrial disease should be considered in patients with hepatic steatosis with normal BMI; lactic acidosis and hypoglycemia; and when associated extrahepatic manifestations, such as neurological signs, myopathy, and developmental delay, are present. In patients with the standard presentation of Alpers syndrome (refractory seizures, psychomotor regression, and liver disease with or without failure), diagnosis can be confirmed by genotyping.

**Case Study 3: Jacob**

Jacob is a 13-year-old Caucasian boy who presented to the emergency department 3 months ago with uncontrolled seizures and respiratory distress. The BMI is 20 kg/m², and his height, weight, and head circumference were all in the 10th–50th percentile for his age. No dysmorphology was noted. Jacob’s medical history showed delayed developmental milestones, as he did not learn to walk until age 24 months. Brain magnetic resonance imaging (MRI) at age 4 years was normal, and an intelligence quotient (IQ) test at age 10 years gave his IQ as 65 (verbal: 75; performance: 58). He has attention deficit hyperactivity disorder (ADHD) including motor and verbal tics. He is the second child of nonconsanguineous parents, and there is no family history of gastrointestinal or liver disease. His initial workup included an abdominal ultrasound that showed hepatomegaly with increased echogenicity. Electroencephalography showed generalized spikes and slow waves with focal sharp waves in the frontal regions. A brain MRI showed bilateral signal changes affecting the thalamus and caudate atrophy of the frontal, cerebellar, and temporal lobes. Routine laboratory workup including a CBC, electrolyte profile, liver enzymes, and renal function was ordered. Sodium valproate (VPA) was prescribed to control seizures (blood level maintained at 650–900 μmol/L). Three months later, the patient returns with increasing fatigue and vomiting.

Patients with Alpers syndrome are at an increased risk for fatal hepatopathy if treated with the anticonvulsant VPA, a successful and popular first-line therapy for seizures that is also used to treat headaches and bipolar disorder. This hepatopathy does not improve with discontinuation of the drug. More than 1 in every 37,000 patients exposed to VPA can develop liver toxicity, with the risk increasing to approximately 1 in every 500 pediatric patients on polytherapy. The National Institutes of Health–funded Drug Induced Liver Injury Network studied 17 patients across 5 centers from 2004 to 2008 and found that a heterozygous defect in POLG was strongly associated with VPA toxicity (odds ratio 23.6).
for characteristic POLG mutations. A467T is the most common mutation in POLG, followed by W748S and G848S. Unless synthetic liver failure exists, liver biopsy should be considered to exclude Wilson’s disease and detect the presence of the histological criteria provided in Table 3. Muscle biopsy may also show depletion of mtDNA in Alpers patients but often provides normal results. Additional criteria are provided in Table 4.

**Treatment**

Treatment of Alpers syndrome is based on symptoms and patient support. There is no cure or means to slow progression.

**Table 3. Major Liver Histological Criteria for Diagnosis of Alpers Syndrome**

<table>
<thead>
<tr>
<th>3 of the Following:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microvesicular steatosis</td>
</tr>
<tr>
<td>Proliferation of the bile ducts</td>
</tr>
<tr>
<td>Hepatocytes dropout or focal necrosis with/without portal inflammation</td>
</tr>
<tr>
<td>Ductal plate collapse</td>
</tr>
<tr>
<td>Parenchymal disorganization or disarray of normal lobular structure</td>
</tr>
<tr>
<td>Bridging fibrosis or cirrhosis</td>
</tr>
<tr>
<td>Regenerative nodules</td>
</tr>
<tr>
<td>Oncyocytic change in scattered hepatocytes not affected by steatosis</td>
</tr>
</tbody>
</table>

**Table 4. Minor Criteria for Diagnosis of Alpers Syndrome**

<table>
<thead>
<tr>
<th>2 of the Following:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevated cerebrospinal fluid (CSF) protein (&gt;60 mg/dL)</td>
</tr>
<tr>
<td>Brain proton magnetic resonance spectroscopy showing reduction of N-acetyl aspartate, normal total creatine, and elevated lactate in affected portions of the cerebral cortex, basal ganglia, and thalamus</td>
</tr>
<tr>
<td>Cerebral volume loss</td>
</tr>
<tr>
<td>At least 1 electroencephalogram with asymmetric or posterior high-amplitude slow waves (200–1000 µV, 0.73–3 Hz) mixed with lower-amplitude polyspike discharges (10–100 µV, 12–25 Hz)</td>
</tr>
<tr>
<td>Optic atrophy or cortical blindness</td>
</tr>
<tr>
<td>Abnormal visual-evoked potentials and normal electroretinogram</td>
</tr>
<tr>
<td>Quantitative mtDNA depletion in skeletal muscle or liver</td>
</tr>
<tr>
<td>Liver or skeletal muscle polymerase γ enzyme activity ≤10%</td>
</tr>
<tr>
<td>Elevated blood or CSF lactate (≥3 mM) on at least 1 occasion with absent acute liver failure</td>
</tr>
<tr>
<td>Isolated complex IV or combined I, III, and IV electron transport complex ≤20% of normal on liver respiratory chain testing</td>
</tr>
<tr>
<td>Sibing with confirmed Alpers syndrome</td>
</tr>
</tbody>
</table>
improvement in muscle cramping and discomfort. Idebenone can be an effective option for treatment of ataxia, especially in patients with discordant visual acuities, and has been shown to be efficacious and safe in both pediatric and adult patients. In addition to coenzyme Q, supplementation of various vitamins, including L-carnitine, folic acid, and creatine monohydrate, is often used in patients with mitochondrial disease. These natural compounds are generally considered harmless at currently prescribed doses, but there is no specific evidence for their efficacy outside of anecdotal reports and recommended treatment protocols do not exist. In general, systemic manifestations of Alpers syndrome preclude the option of liver transplantation as treatment. Liver transplantation has been attempted in VPA-induced liver failure with successful engraftment in most cases, but these patients still died soon after as a result of progressive neurological deterioration. Conversely, patients who have disease with deoxyguanosine kinase deficiency and no central nervous system involvement may benefit from liver transplantation.

**Case Study 3: Follow-Up**

Increased fatigue and vomiting indicate a need to evaluate Jacob further. Additional laboratory workup is ordered, and relevant results include an ALT of 306 IU/L, total bilirubin of 7.7 mg/dL, international normalized ratio of 2.2, ammonia level of 123 mg/L, and lactate level of 3.9 mmol/L. The international normalized ratio did not improve with vitamin K repletion. These symptoms and results are indicative of acute liver failure. The patient also shows many warning signs of Alpers syndrome, including delayed development, uncontrolled seizures, and inability to concentrate (previous diagnosis of ADHD). The VPA regimen is stopped immediately to avoid any further contribution to liver disease or hepatopathy, and a liver biopsy is ordered. Biopsy shows microvesicular steatosis, bile duct proliferation, and bridging cirrhosis, confirming the diagnosis. Although there is no approved treatment for Alpers syndrome, he is put on a trial of supplements that include coenzyme Q and L-carnitine and monitored for symptom improvement.

**Summary**

Obesity causes most fatty liver disease; however, it is not the cause of all fatty liver disease. Other causes of NAFLD include cystic fibrosis, Wilson’s disease, total parenteral nutrition, diabetes mellitus, lipodystrophies, fatty acid oxidation defects, mitochondrial hepatopathies (such as Alpers syndrome), LAL deficiency, drug toxicity, and rapid weight loss. Clues to NAFLD not caused by obesity include absence of obesity, microvesicular steatosis predominance, medication and herb exposure, clinical features other than obesity, and significant hypercholesterolemia. It is also important to note that, whereas these diseases are examples of nonobese causes of fatty liver disease, it is still possible for them to occur in obese patients, and therefore, care providers should continue to entertain them in their differential diagnosis of NAFLD in both obese and nonobese individuals.

**References**


